Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma

Human Gene Therapy

Volumn 7, Issue 5, 1996, Pages 627-635

  Cool, Vincent ^a   Pirotte, Benoît ^a   Gérard, Catherine ^a   Dargent, Jean Louis ^a   Baudson, Nathalie ^a   Levivier, Marc ^a   Goldman, Serge ^a   Hildebrand, Jerzy ^a   Brotchi, Jacques ^a   Velu, Thierry ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TRANSFER; GENETIC TRANSDUCTION; GLIOSARCOMA; HERPES SIMPLEX VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MARKER GENE; NONHUMAN; RAT; RETROVIRUS; TUMOR LOCALIZATION;

EID: 19144364318     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.5-627     Document Type: Article

References (36)

1. BARBA, D., HARDIN, J., RAY, J., and GAGE, F.H. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
2. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352.
3. BLACK, P.M. (1991). Brain tumors. N. Engl. J. Med. 324, 1555-1564.
4. BLAESE, R.M. (1995). Suicide genes. Task Force Rev. 6, 5.
5. CARUSO, M., PANIS, Y., GAGANDEEP, S., HOUSSIN, D., SALZMANN, J.L., and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024-7028.
6. CHIANG, Y.L. (1994). Characterization of a new herpes simplex thymidine kinase retroviral producer cell. Cancer Gene Ther. 1, 306.
7. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
8. CULVER, K.W., VAN GILDER, J., LINK, C.J., CARLSTROM, T., BUROKER, T., YUH, W., KOCH, K., SCHABOLD, K., DOORNBAS, S., WETJEN, B., and BLAESE, R.M. (1994). Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
9. EZZEDDINE, Z.D., MARTUZA, R.L., PLATIKA, D., SHORT, M.P., MALICK, A., CHOI, B., and BREAKEFIELD, X.O. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608-614.
10. FLETCHER, C., SAWCHUK, R., CHINNOCK, B., DE MIRANDA, P., and BALFOUR, H.H.J. (1986). Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40, 281-286.
11. GOLUMBEK, P.T., HAMZEH, F.M., JAFFEE, E.M., LEVITSKY, H., LIETMAN, P.S., and PARDOLL, D.M. (1992). Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J. Immunother. 12, 224-230.
12. IZQUIERDO, M., CORTES, M., DE FELIPE, P., MARTIN, V., DIEZ-GUERRA, J., TALAVERA, A., and PEREZ-HIGUERAS, A. (1995). Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. 2, 66-69.
13. JACOBSON, M.A., DE MIRANDA, P., CEDERBERG, D.M., BURNETTE, T., COBB, E., BRODIE, H.R., and MILLS, J. (1987). Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Chemother. 31, 1251-1254.
14. LEVIVIER, M., HOLEMANS, S., TOGASAKI, D.M., MALOTEAUX, J.-M., BROTCHI, J., and PRZEDBORSKI, S. (1994). Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol. Res. 16, 194-200.
15. MILLER, A.D., and BUTTIMORE, C. (1988). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
16. MILLER, A.D., and ROSMAN, J.R. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-990.
17. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
18. MOOLTEN, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287.
19. MOOLTEN, F.L., WELLS, J.M., HEYMAN, R.A., and EVANS, R.M. (1990). Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1, 125-134.
20. MOOLTEN, F.S., WELLS, J.M., and MROZ, P.J. (1992). Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett. 64, 257-263.
21. MORANTZ, R.A., WOOD, G.W., FOSTER, M., CLARK, M., and GOLLAHON, K. (1979). Macrophages in experimental and human brain tumors. Part 1: Studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J. Neurosurg. 50, 298-304.
22. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DEVROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intratumoral transaction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
23. PALMA, L., DI LORENZO, N., and GUIDETTI, B. (1978). Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J. Neurosurg. 49, 854-861.
24. PEEBLES, P.T., (1975). An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C, and the feline-primate viruses RD-114/CCC/M-7. Virology 67, 288-291.
25. RAM, Z., CULVER, K.W., WALBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993a). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
26. RAM, Z., CULVER, K.W., WALBRIDGE, S., FRANK, J.A., BLAESE, R.M., and OLDFIELD, E.H. (1993b). Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg. 79, 400-407.
27. RAM, Z., WALBRIDGE, S., HEISS, J.D., CULVER, K.W., BLAESE, R.M., and OLDFIELD, E.H. (1994a). In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80, 535-540.
28. RAM, Z., WALBRIDGE, S., SHAWKER, T., CULVER, K.W., BLAESE, R.M., and OLDFIELD, E.H. (1994b). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81, 256-260.
29. RIDLEY, A., and CAVANAGH, J.B. (1971). Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 94, 117-124.
30. SCHMIDEK, H.H., NIELSEN, S.L., SCHILLER, A.L., and MESSER, J. (1971). Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J. Neurosurg. 34, 335-340.
31. SHORT, M.P., CHOI, B.C., LEE, J.K., MALICK, A., BREAKEFIELD, X.O., and MARTUZA, R.L. (1990). Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427-439.
32. SOBOL R.E. and SCANLON, K.J. (1994). Clinical protocols. Cancer Gene Ther. 1, 289-295.
33. TAKAMIYA, Y., SHORT, M.P., EZZEDDINE, Z.D., MOOLTEN, F.L., BREAKEFIELD, X.O., and MARTUZA, R.L. (1992). Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33, 493-503.
34. TAKAMIYA, Y., SHORT, M.P., MOOLTEN, F.L., FLEET, C., MINETA, T., BREAKEFIELD, X.O., and MARTUZA, R.L. (1993). An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg. 79, 104-110.
35. TAPSCOTT, S.J., MILLER, A.D., OLSON, J.M., BERGER, M.S., GROUDINE, M., and SPENCE, A.M. (1994). Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185-8189.
36. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.